Clinical Trial Update: Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating belvarafenib in combination with cobimetinib for NRAS-mutant locally advanced or metastatic melanoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Belvarafenib (belvarafenib)
• Cobimetinib (cobimetinib)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Advanced or Metastatic Melanoma | Phase 2 | Status: RECRUITING